Loading…
OCTREOTIDE is a brand name for Octreotide. The medicine, its uses, side effects and dosage are the same regardless of brand.
Used for: Symptomatic control and reduction of growth hormone (GH) and IGF-1 plasma levels in patients with acromegaly who are inadequately controlled by surgery or radiotherapy. Octreotide is also indicated for acromegalic patients unfit or unwilling to undergo surgery, or in the interim period until radiotherapy becomes fully…
Verbatim from this product's MHRA label. Tap a section to expand.
) injection every 8 or 12 hours. 5 ng/mL; IGF-1 within normal range) and clinical symptoms, and on tolerability. 3 mg. 5 mg per day should not be exceeded. For patients on a stable dose of Octreotide, assessment of GH and IGF-1 should be made every 6 months.
If no relevant reduction in GH levels and no improvement in clinical symptoms have been achieved within 3 months of starting treatment with Octreotide, therapy should be discontinued. c. injection. 2 mg 3 times daily. Under exceptional circumstances, higher doses may be required.
Maintenance doses have to be adjusted individually. In carcinoid tumours, if there is no beneficial response within 1 week of treatment with Octreotide at the maximum tolerated dose, therapy should not be continued. c. injection for 7 consecutive days, starting on the day of surgery at least 1 hour before laparotomy.
) infusion. Octroetide can be used in dilution with physiological saline. v. doses of up to 50 micrograms/hour for 5 days. c. injection. The dose can be adjusted according to the responses of TSH and thyroid hormones. At least 5 days of treatment will be needed to judge the efficacy.
Use in the elderly There is no evidence of reduced tolerability or altered dosage requirements in elderly patients treated with Octreotide. Use in children Experience with Octreotide in children is limited. Use in patients with impaired liver function In patients with liver cirrhosis, the half-life of the drug may be increased, necessitating adjustment of the maintenance dosage.
c. injection, therefore no dose adjustment of Octreotide is necessary. ) infusion after dilution. 6.
Summary of the safety profile The most frequent adverse reactions reported during octreotide therapy include gastrointestinal disorders, nervous system disorders, hepatobiliary disorders, and metabolism and nutritional disorders. The most commonly reported adverse reactions in clinical trials with octreotide administration were diarrhoea, abdominal pain, nausea, flatulence, headache, cholelithiasis, hyperglycaemia and constipation.
g. decreased thyroid stimulating hormone [TSH], decreased total T4, and decreased free T4), loose stools, impaired glucose tolerance, vomiting, asthenia, and hypoglycaemia. Tabulated list of adverse reactions The following adverse drug reactions, listed in Table 1, have been accumulated from clinical studies with octreotide: Adverse drug reactions (Table 1) are ranked under heading of frequency, the most frequent first, using the following convention: very common (≥1/10); common (≥1/100, <1/10); uncommon (≥1/1 000, <1/100); rare (≥1/10 000, <1/1 000) very rare (<1/10 000), including isolated reports.
Within each frequency grouping, adverse reactions are ranked in order of decreasing seriousness. g. decreased TSH, decreased total T4, and decreased free T4) Hepatobiliary disorders Very common: Cholelithiasis Common: Cholecystitis, biliary sludge, hyperbilirubinaemia Metabolism and nutrition disorders Very common: Hyperglycaemia Common: Hypoglycaemia, impaired glucose tolerance, anorexia Uncommon: Dehydration General disorders and administration site conditions Very common: Injection site reactions Common: Asthenia Investigations Common: Elevated transaminase levels Skin and subcutaneous tissue disorders Common: Pruritus, rash, alopecia Respiratory disorders Common: Dyspnoea Cardiac disorders Common: Bradycardia Uncommon: Tachycardia Post-marketing Spontaneously reported adverse reactions presented in Table 2, are reported voluntarily and it is not always possible to reliably establish frequency or a causal relationship to drug exposure.
g. visual field defects), it is essential that all patients be carefully monitored. If evidence of tumour expansion appears, alternative procedures may be advisable. The therapeutic benefits of a reduction in growth hormone (GH) levels and normalisation of insulin-like growth factor 1 (IGF-1) concentration in female acromegalic patients could potentially restore fertility.
6). Thyroid function should be monitored in patients receiving prolonged treatment with octreotide. Hepatic function should be monitored during octreotide therapy. Cardiovascular related events Common cases of bradycardia have been reported.
5). Atrioventricular blocks (including complete atrioventricular block) were reported in patients receiving high doses of continuous infusion (100 micrograms/hour) and in patients receiving bolus octreotide intravenously (50 micrograms bolus followed by 50 micrograms/hour continuous infusion).
2). Patients who receive high doses of intravenous octreotide should be kept under appropriate cardiac monitoring. 8). Ultrasonic examination of the gallbladder before, and at about 6- to 12-month intervals during Octreotide therapy is therefore recommended.
Pancreatic function Pancreatic exocrine insufficiency (PEI) has been observed in some patients receiving octreotide therapy for gastroenteropancreatic neuroendocrine tumours. Symptoms of PEI can include steatorrhea, loose stools, abdominal bloating, and weight loss.
Screening and appropriate treatment for PEI according to clinical guidelines should be considered in symptomatic patients. GEP endocrine tumours During the treatment of GEP endocrine tumours, there may be rare instances of sudden escape from symptomatic control by Octreotide, with rapid recurrence of severe symptoms.
If the treatment is stopped, symptoms may worsen or recur. Glucose metabolism Because of its inhibitory action on growth hormone, glucagon, and insulin, Octreotide may affect glucose regulation. Post-prandial glucose tolerance may be impaired and, in some instances, the state of persistent hyperglycaemia may be induced as a result of chronic administration.
1.
Not medical advice. Always read the patient information leaflet and follow your prescriber or pharmacist.
Other brands of Octreotide in United Kingdom.
Know a brand we are missing in United Kingdom? Suggest a brand →
Brand names are compiled from public regulatory records for active-ingredient mapping only. Drugvu is not affiliated with any manufacturer. This is not medical advice.
Table 2 Adverse drug reactions derived from spontaneous reports Blood and lymphatic system disorders Thrombocytopenia Immune system disorders Anaphylaxis, allergy/hypersensitivity reactions Skin and subcutaneous tissue disorders Urticaria Hepatobiliary disorders Acute pancreatitis, acute hepatitis without cholestasis, cholestatic hepatitis, cholestasis, jaundice cholestatic jaundice Cardiac disorders Arrhythmias Investigations Increased alkaline phosphatase levels, increased gamma glutamyl transferase levels Description of selected adverse reactions Gallbladder and related reactions Somatostatin analogues have been shown to inhibit gallbladder contractility and decrease bile secretion, which may lead to gallbladder abnormalities or sludge.
c. octreotide acetate. The incidence in the general population (aged 40 to 60 years) is 5 to 20%. If gallstones do occur, they are usually asymptomatic; symptomatic stones should be treated either by dissolution therapy with bile acids or by surgery.
Gastrointestinal disorders In rare instances, gastrointestinal side effects may resemble acute intestinal obstruction, with progressive abdominal distension, severe epigastric pain, abdominal tenderness and guarding. The frequency of gastrointestinal adverse events is known to decrease over time with continued treatment.
c. administration, that is, by injecting between meals or on retiring to bed. Hypersensitivity and anaphylactic reactions Hypersensitivity and allergic reactions have been reported during post-marketing experience. When these occur, they mostly affect the skin, rarely the mouth and airways.
Isolated cases of anaphylactic shock have been reported. c. injection, with redness and swelling, rarely lasting more than 15 minutes. Local discomfort may be reduced by allowing the solution to reach room temperature before injection, or by injecting a smaller volume using a more concentrated solution.
Metabolism and nutrition disorders Although measured faecal fat excretion may increase, there is no evidence to date that long-term treatment with octreotide has led to nutritional deficiency due to malabsorption. c. treatment and resolved on withdrawal of the drug.
c. treatment. Cardiac disorders Bradycardia is a common adverse reaction with somatostatin analogues. In both acromegalic and carcinoid syndrome patients, ECG changes were observed such as QT prolongation, axis shifts, early repolarisation, low voltage, R/S transition, early R wave progression, and non-specific ST-T wave changes.
4). ) in patients with cirrhosis of the liver. This is reversible after discontinuation of treatment. Reporting of suspected adverse reactions Reporting […]
Hypoglycaemia has also been reported. In patients with insulinomas, octreotide, because of its greater relative potency in inhibiting the secretion of GH and glucagon than that of insulin, and because of the shorter duration of its inhibitory action on insulin, may increase the depth and prolong the duration of hypoglycaemia.
These patients should be closely monitored during initiation of Octreotide therapy and at each change of dosage. Marked fluctuations in blood glucose concentration may possibly be reduced by smaller, more frequently administered doses.
Insulin requirements of patients with type I diabetes mellitus therapy may be reduced by administration of Octreotide. In non-diabetics and type II diabetics with partially intact insulin reserves, Octreotide administration can result in post-prandial increases in glycaemia.
It is therefore recommended to monitor glucose tolerance and antidiabetic treatment. Oesophageal varices Since, following bleeding episodes from oesophageal varices, there is an increased risk for the development of insulin-dependent diabetes or for changes in insulin requirement in patients with pre-existing diabetes, an appropriate monitoring of blood glucose levels is mandatory.
c. injection site only at the highest dose (about 8 times the maximum human dose based on body surface area). c. injection site in a 52-week dog toxicity study. There have been no reports of tumour formation at the injection sites in patients treated with Octreotide for up to 15 years.
3). Nutrition Octreotide may alter absorption of dietary fats in some patients. Depressed vitamin B12 levels and abnormal Schilling’s tests have been observed in some patients receiving octreotide therapy. Monitoring of vitamin B12 levels is recommended during therapy with Octreotide in patients who have a history of vitamin B12 deprivation.
Sodium content This medicinal product contains less than 1 mmol (23 mg) sodium per dose. Patients on low sodium diets can be informed that this medicinal product is essentially ‘sodium-free’.